Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
British Journal of Cancer
|
March 10, 2005
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
J P Delord, J Y Pierga, V Dieras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2003
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial)
L Zelek, R Bugat, D Cherqui, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study
E Alouani, C Canivet, B Bournet, et al.
Oncogene
|
November 11, 2009
A 'DNA replication' signature of progression and negative outcome in colorectal cancer
M-J Pillaire, J Selves, K Gordien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV
F A Lévi, V Boige, M Hebbar, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 13, 2018
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
Y Touchefeu, R Guimbaud, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
A R Thierry, S El Messaoudi, C Mollevi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2017
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
T Walter, D Tougeron, E Baudin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2026
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer
S Rao, E Samalin-Scalzi, L Evesque, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 28, 2012
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm
Z Reguiai, J B Bachet, C Bachmeyer, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
British Journal of Cancer
|
March 10, 2005
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
J P Delord, J Y Pierga, V Dieras, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2003
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial)
L Zelek, R Bugat, D Cherqui, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study
E Alouani, C Canivet, B Bournet, et al.
Oncogene
|
November 11, 2009
A 'DNA replication' signature of progression and negative outcome in colorectal cancer
M-J Pillaire, J Selves, K Gordien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV
F A Lévi, V Boige, M Hebbar, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 13, 2018
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
Y Touchefeu, R Guimbaud, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
A R Thierry, S El Messaoudi, C Mollevi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2017
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
T Walter, D Tougeron, E Baudin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2026
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer
S Rao, E Samalin-Scalzi, L Evesque, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 28, 2012
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm
Z Reguiai, J B Bachet, C Bachmeyer, et al.
Page
of 6